PT - JOURNAL ARTICLE AU - Jessica R. Schumacher AU - Whitney P. Witt AU - Mari Palta AU - Noelle K. LoConte AU - Susan M. Heidrich AU - Amy Trentham-Dietz AU - Nancy Pandhi AU - Maureen A. Smith TI - Cancer Screening of Long-Term Cancer Survivors AID - 10.3122/jabfm.2012.04.110118 DP - 2012 Jul 01 TA - The Journal of the American Board of Family Medicine PG - 460--469 VI - 25 IP - 4 4099 - http://www.jabfm.org/content/25/4/460.short 4100 - http://www.jabfm.org/content/25/4/460.full SO - J Am Board Fam Med2012 Jul 01; 25 AB - Background: Although 64% of cancer survivors are expected to live at least 5 years beyond diagnosis, the receipt of cancer screening by this population is unclear. The objective of this study was to assess the relation between a cancer diagnosis and future cancer screening, exploring provider-, patient-, and cancer-specific factors that explain observed relationships. Methods: The Wisconsin Longitudinal Study (WLS) and Wisconsin Tumor Registry were used to identify 2 participant groups: 415 patients diagnosed with nonmetastatic cancer between 1992 to 1993 (before cancer) and 2003 to 2004 (after cancer) and 4680 controls (no cancer). Adjusted average predicted probabilities of cancer screening were estimated with models that first did not include and then included, provider (provider relationship length), participant (depressive symptoms per the Center for Epidemiologic Studies Depression Scale), and cancer-specific (time since diagnosis) factors. Participants with a history of cancer associated with a given screening test were then excluded to assess whether relationships are explained by screening for recurrence versus second cancers. Results: Female cancer survivors were more likely than no-cancer controls to undergo pelvic/Papanicolaou screening (survivors: 70%, 95% confidence interval [CI]: 63% to 76%; controls: 61%, 95% CI: 59% to 63%) and mammography screening (survivors: 86%, 95% CI: 78% to 90%; controls: 76%, 95% CI: 74% to 77%), though male cancer survivors were not more likely to receive prostate exams (survivors: 76%, 95% CI: 70% to 82%; controls: 69%, 95% CI: 67% to 71%). After excluding people with a history of the cancer being screened for, there were few significant differences in cancer screening between short- or long-term survivors (≥5 years) and no-cancer controls. Relationships were not sensitive to adjustment for provider or participant factors. Conclusions: The significant positive differences in cancer screening between people with and without cancer can be explained by screening for recurrence. Long-term cancer survivors are not more likely to receive follow-up screening for second cancers. This information should be used by providers to ensure patients receive recommended follow-up preventive care.